POLYSACCHARIDE-POLYAMINE COPOLYMER AND USE THEREOF IN REDUCING URIC ACID CONCENTRATION IN PLASMA
0 Assignments
0 Petitions
Accused Products
Abstract
Disclosed is a pharmaceutical composition for treating hyperuricemia (HUA). The pharmaceutical composition includes a polysaccharide-polyamine copolymer and a pharmaceutically acceptable salt thereof as active ingredients. The polysaccharide-polyamine copolymer is formed by copolymerization of the following two parts: a selectively oxidized polysaccharide with 2,3-dialdehydo, and a polyamine with an amino functional group; the polyamine with an amino functional group and the selectively oxidized polysaccharide with 2,3-dialdehydo can form a net structure by means of covalent crosslinking, resulting in a hydrogel with an amino functional group or a granular polysaccharide-polyamine copolymer, wherein the amino functional group in the hydrogel with an amino functional group or the granular polysaccharide-polyamine copolymer can be protonated so as to form a cationic copolymer of a three-dimensional network structure having a protonated site, and the nitrogen content of the cationic copolymer and the nitrogen content of the polysaccharide-polyamine copolymer are above 12.3 wt %, and both the cationic copolymer and the polysaccharide-polyamine copolymer are water-insoluble.
-
Citations
49 Claims
-
1-27. -27. (canceled)
-
28. A pharmaceutical composition for treatments of hyperuricemia, the pharmaceutical composition comprises an amino-polysaccharide copolymer and a pharmaceutically acceptable salt thereof as an active ingredient, the amino-polysaccharide copolymer is a copolymerization product of the following two parts:
-
a selectively oxidized polysaccharide having a 2,3-dialdehyde moiety, and a amino polymer which provides an amino functionality; the amino polymer cross linking the selectively oxidized polysaccharide having a 2,3-dialdehyde moiety to form a net-like structure and finally to provide a hydrogel having an amino functionality or a particulate amino-polysaccharide copolymer, amino functionalities of the hydrogel having an amino functionality or the particulate amino-polysaccharide copolymer can be protonated to form a cationic copolymer having three dimensional network structure and protonation sites, a nitrogen content of the cationic copolymer or the amino-polysaccharide copolymer is at least 12.3% weight percent, or at least 15% weight percent, or at least 22% weight percent, or at least 40% weight percent, the cationic copolymer and the amino-polysaccharide copolymer are both insoluble in water. - View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
-
-
39. A use of a pharmaceutical composition comprising an amino-polysaccharide copolymer and a pharmaceutically acceptable salt thereof as an active ingredient in the preparation of a medicament for the treatment of hyperuricemia, wherein, the amino-polysaccharide copolymer is a copolymerization product of the following two parts:
-
a selectively oxidized polysaccharide having a 2,3-dialdehyde moiety, and a amino polymer which provides an amino functionality; the amino polymer cross linking the selectively oxidized polysaccharide having a 2,3-dialdehyde moiety to form a net-like structure and finally to provide a hydrogel having an amino functionality or a particulate amino-polysaccharide copolymer, amino functionalities of the hydrogel having an amino functionality or the particulate amino-polysaccharide copolymer can be protonated to form a cationic copolymer having three dimensional network structure and protonation sites, a nitrogen content of the cationic copolymer or the amino-polysaccharide copolymer is at least 12.3% weight percent, or at least 15% weight percent, or at least 22% weight percent, or at least 40% weight percent, the cationic copolymer and the amino-polysaccharide copolymer are both insoluble in water. - View Dependent Claims (40, 41, 42, 43, 44, 45, 46, 47, 48, 49)
-
Specification